United Kingdom

People: Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

4:35pm BST
Change (% chg)

€0.06 (+0.65%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lussier, Michel 

Mr. Michel E. Lussier has served as Chairman of the Board and Co-Founder since Cardio3 Biosciences SA inception in July 2007. He obtained a degree of Bachelor of Sciences in Electrical Engineering and a degree of Master in Sciences in Biomedical Engineering at the University of Montreal. He also holds a Masters of Business Administration from INSEAD (European Institute of Business Administration), France. He was also co-Founder and Chairman of the Board of Directors of the Company’s predecessor entity, Cardio3 SA, from its incorporation in 2003 until its liquidation in 2008. From September 1994 until its acquisition by Guidant in 1998, Michel led, as Vice-President and General Manager of European Operations, the European subsidiary of InControl Corp. From October 1998 to March 2002, Michel served as Vice President, General Manager Europe of Novoste Corp. From July 2002 to 2007, he assumed the position of Volcano Vice President, General Manager of Europe, Africa and Middle East for Volcano Corporation. From 2007 until October 2012, he served as Volcano Group President, Advanced Imaging Systems, Global Clinical & Scientific Affairs and General Management of Europe, Africa and Middle East. Since October 2012, he serves as President, Clinical and Scientific Affairs for Volcano. In February 2002, he founded Medpole SA. He brings 15 years of operational experience with Medtronic Inc, where he led the company's core business in Europe as Business Director Cardiac Pacing. Additionally, Mr. Lussier is Chief Executive Officer of Medpole SA and has been Chairman of a number of committees within Eucomed. He also served on several start-up boards for medical devices. He is Member of the Company's Nomination and Remuneration Committee.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --